AccessSeller-approved · under NDA

This workspace is documentation-first. Buyers evaluate the data dictionary, schema, provenance and quality reporting before any sample is produced, and samples are de-identified. Raw records, credentials and system access are never provided here.

OverviewPharmaceuticals & Life Sciences
Reference
#1377
Region
APAC
Size band
50–100 employees
Years operating
28
Continuous history
13 yrs
Volume
760,000+ records
Score
72/100
Status
IN DILIGENCE
Data dictionary3 record families
  • Case Managementdocumented
  • Quality Recordsdocumented
  • Financial Recordsdocumented
Schema and keysJoin surface

Systems of record

Veeva VaultSAPSnowflakeMicrosoft 365

Cross-system connectivity

Veeva VaultSAPSnowflake

Records join on stable operational keys, allowing a single case to be traced across systems from initiation to financial close.

SampleDe-identified · post rights review

Samples are produced only after the rights review below is complete and the de-identification plan is agreed. A sample is a structured extract with entity and person identifiers pseudonymised, free-text redacted where required, and volumes capped.

Sample not yet released — pending rights review

ProvenanceHow the data was generated

All records were generated as a by-product of the seller's own operations inside systems the seller controls. No scraped, purchased or third-party-licensed corpora are included.

Workflow families captured

  • Deviation intake and investigation
  • CAPA approval chain
  • Submission dossier assembly
  • Site monitoring visits
RightsDiligence states, not legal advice
  • OwnershipREADY

    Company-generated operational records in owned tenants.

  • Source systemsREADY

    Veeva Vault, SAP, Snowflake, Microsoft 365.

  • Third-party dataREVIEW REQUIRED

    CRO-generated monitoring reports.

  • Customer / client dataREVIEW REQUIRED

    Investigator and subject references in monitoring records.

  • Employee dataREVIEW REQUIRED

    Approver identities appear in workflow audit trails.

  • Potential PIIREVIEW REQUIRED

    Names and work contact details appear in free text.

  • Contract restrictionsRESTRICTED

    Sponsor and CRO agreements restrict transfer.

  • Licensing permissionsNOT VERIFIED

    Pending rights review.

  • Retention periodREADY

    13 years retained; no scheduled destruction.

  • Geographic restrictionsREADY

    APAC operations only.

  • Intended AI useREVIEW REQUIRED

    Seller prefers training plus evaluation, no resale.

  • De-identification requirementsRESTRICTED

    Entity and person pseudonymisation required pre-sample.

PrivacyDe-identification plan
PII risk
MODERATE
De-identification difficulty
HIGH
Licensing readiness
RESTRICTED

Entity and person pseudonymisation, suppression of contact fields and review of free-text comment threads are applied before any extract leaves the seller environment.

QualityReported and verified
Volume
MODERATE
Historical depth
MODERATE
Workflow complexity
MODERATE
Cross-system
MODERATE
Uniqueness
HIGH
Data quality
HIGH
Outcome labels
HIGH
Workflow documentationAgent-relevant
01

Deviation intake and investigation

02

CAPA approval chain

03

Submission dossier assembly

04

Site monitoring visits

Applicable AI use cases

Vertical AI agentsEvaluation benchmarksDocument reasoning
Technical documentationDelivery
Delivery format
Structured extracts (Parquet / CSV) + documentation
Transfer
Seller-controlled secure transfer, audited
Refresh
Negotiable: one-time, quarterly or annual
Access controls
Named recipients under NDA
Licensing termsSeller preference
Preference
Restricted-environment evaluation only
Potential data value
Assessment available after diligence
Qualified buyer interest
6

Terms are negotiated per buyer. SentryRights does not represent any figure as a valuation and does not represent that this asset is licensable before rights review completes.

Demo data — illustrative sample listings, not live marketplace records